Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients

The development of BMS-986094 (Bristol-Myers Squibb), a nucleotide-polymerase inhibitor for the treatment of chronic hepatitis C (HCV) infection, was terminated back in August 2012, but a new retrospective review analyzing adverse events provides an in-depth look at the cardiotoxicity associated with the investigational agent. The findings may have profound implications for other drugs in late-stage testing or others approved for use.

Published
29 September 2014
From
Medscape (requires registration)
Patent landscape for hepatitis issued by WHO

The World Health Organization has published an analysis of the patent situation for new hepatitis treatments, and a call for possible pharmaceutical products for prequalification.

Published
29 September 2014
From
Intellectual Property Watch
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

Gilead Sciences, Inc. GILD, +0.97% today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Harvoni®,an investigational once-daily tablet combining the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg, for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Published
29 September 2014
From
Gilead press release
Why Gilead’s Recent Deal with Generic Producers for its Hepatitis C Drugs (Sofosbuvir and Ledipasvir) is a Sham

Under the pretext of increasing access to its hepatitis C treatment, the new deal signed by Gilead for their HCV drugs sofosbuvir (Sovaldi©) and ledipasvir hides a clear strategy to prevent fair generic competition. The International Treatment Preparedness Coalition (ITPC) denounces Gilead’s strategy to block generic competition.

Published
25 September 2014
From
ITPC
NICE consults on draft guidance on the drug simeprevir (Olysio) for treating hepatitis C

In draft guidance published today healthcare guidance body NICE has recommended simeprevir (Olysio, Janssen) as a treatment option for some people with chronic hepatitis C.

Published
25 September 2014
From
NICE
As Gilead Mulls Price of Next Hepatitis C Drug, Top Activist Refutes "Bogus" Math

Sovaldi, the hepatitis C drug that costs US$1,000 a pill and US$84,000 for a full course of treatment, is about to look a little bit more reasonable by comparison. According to industry analysts, the price for Gilead's next hepatitis C drug (a combination of Sovaldi and the experimental drug ledipasvir), which the U.S. Food and Drug Administration may approve as soon as next month, could come with a price tag of US$95,000 for a course of treatment.

Published
24 September 2014
From
TheBody.com
HCV antibody testing may miss recent infections in gay men living with HIV

Nucleic acid testing should be used to diagnose acute hepatitis C virus (HCV) infections in gay men living with HIV, Dutch research published in the online edition

Published
23 September 2014
By
Michael Carter
Hepatitis C: Sit in of European patients to request access to new medicines, on occasion of the informal meeting of European Health Ministers in Milan

In support of the Call to EU Ministers of Health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding Universal Access to Curative Hepatitis C Treatment in the EU an beyond (attached), EPAC, Lila and Nadir with the support of the subscribers of the call, organized a “Sit-In” of people living with hepatitis C and their allies on the 22nd of September, at the Mico Conference Center, in Milan, starting at 11:20 am, to advocate for, and demand, a clear political and public health commitment and leadership from the twenty eight member states of the European Union

Published
22 September 2014
From
EATG
The new $84,000 hepatitis C treatment is losing momentum, for now

Data released by CVS Health on Tuesday show that use of Sovaldi has slowed down since May after the drug's record-setting start last December. The slowdown can partly be explained by the health-care industry's anticipation of more hepatitis C treatments soon hitting the market, including another one from Gilead that could gain FDA approval any day now.

Published
22 September 2014
From
Washington Post
STIs and Hep C levels at all-time high in Australia

The Kirby Institute’s Annual Surveillance Report suggests a number of STIs are continuing to increase, with syphilis and gonorrhoea leading the charge. Hepatitis C infections are also a growing health issue with more people now dying from viral hepatitis infection than from HIV when it was in its peak in the 80s and 90s.

Published
22 September 2014
From
Gay News Network
← First12345...143Next →

Filter by country